All News

Colleen McCabe, PharmD, BCOP, emphasizes the importance of a proactive and tailored approach for pharmacists educating patients on skin cancer risks specific to their communities.

The market is sensitive to both upstream and downstream pressures that impact drug pricing.

The specialty drug market has exploded, and will continue to grow across sectors such as oncology and neurology.

A lack of clarity around certain provisions of the Inflation Reduction Act has presented challenges to payers.

Understanding the goals of each party is the first step to a successful collaboration.

Collaboration between health system specialty pharmacists and pharmaceutical manufacturers can benefit patients in the long run.

Addressing requirements around FDA interchangeability designations can increase the adoption of biosimilar substitutions at the pharmacy level.

A recent bill introduced to Congress is intended to prevent product hopping, a practice that extends exclusivity and hinders the adoption of biosimilar therapies.

Distributors can help manufacturers create patient access programs that reduce costs, copays, and co-insurance.

One notable incentive includes the launch of biosimilars at both low- and high wholesale acquisition costs.

Pharmacists can help financial decision makers understand the value of biosimilar therapies.

Savings associated with biosimilar uptake are projected to reach $181 billion through 2027.

The expertise of health system specialty pharmacists, combined with better adherence and better affordability, leads to better patient outcomes.

Paying for these new therapies, that may be curative for patients, remains a challenge.

From medication adherence to patient counseling, clinical pharmacists at health system specialty pharmacies can play a role in reducing health care costs.

According to Scott Soefje, PharmD, understanding nuances across sites of care can help health care providers optimize patient care delivery while ensuring financial viability across all settings.

Karen Fancher, PharmD, addresses how hearing the perspectives of colleagues can offer invaluable support to shape individualized approaches to ethical dilemmas in oncology pharmacy.

While prioritizing either cost or margin may be necessary at a site of care, big picture items, such as societal responsibility and long-term health care affordability, should guide financial analyses, said Scott Soefje, PharmD.

According to Kirollos Hanna, PharmD, although similarities exist between bispecific therapies in the myeloma space, health care providers should take special note of practical differences and nuances associated with each when operationalizing them at their site of care.

As the potential grows to use emerging bispecifics in earlier lines of myeloma therapy, so does the potential to induce better patient outcomes, said Kirollos Hanna, PharmD.

Winner of SingleCare's Best of the Best: Best Pharmacist, Nguyen joined Drug Topics® to discuss how he's helped patients during adverse conditions and what makes for a successful patient encounter.

Winner of SingleCare's Best of the Best: Best Pharmacy Technician, Santon joined Drug Topics® to discuss what pharmacy technicians can do for patients and why it's so important to her for every patient to afford their medication.

CPESN payers and their success stories.

Did you miss our coverage of the 2021 SingleCare Best of the Best Pharmacy Awards? View all four interviews in our video gallery below.